International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

4-Aryl-1,4-dihydropyrimidines as Potential agents against Congestive Heart Failure: A Review

Author Affiliations

  • 1Department of Chemistry, D.A.V College, Chandigarh, INDIA

Res.J.chem.sci., Volume 4, Issue (7), Pages 99-106, July,18 (2014)


Owing to great possibilities of biological activities exhibited by pyrimidines and dihydropyrimidines, these are subject of great interest which helps in developing new synthetic routes, with innovative methods and using new technology. A series of tetrahydropyrimidines were prepared under microwave irradiations which was an efficient, time saving method also resulting in good yield. Tetrahydropyrimidines were converted to S-alky/benzyl-1,4-dihydropyrimidines. The purpose for synthesizing these dihydroprimidines was to design aza-analog of nifedipine. Pharmacological activities were determined for these synthesized compounds where standard drug taken for comparison purpose was nifedipine. The best part came out after screening these compounds for biological activity as these were smooth muscle relaxant, anti hypertensive and can be used in Congestive Heart Failure. These compounds edge over nifedipine in their biological activity as nifedipine cannot be used and if administered for Congestive Heart Failure, it can worsen the condition.


  1. Atwal K.S., Swanson B.N., Unger S.E., Floyd D.M., Moreland S., Hedberg A and O’Reilly B.C., Dihydropyrimidine calcium channel blockers. 3.3-Carbamoyl-4-aryl-1,2,3,4-tetrahydro-6-methyl-5-pyrimidinecarboxylic acid esters as orally effective antihypertensive agents, J Med Chem., 34(2), 806-811 (1991)
  2. Rovnyak G.C., Atwal, K.S., Hedberg, A., Kimball, S.D., Moreland, S., Gougoutas, J.Z., O’Reilly B.C., Schwartz J. and Malley, M.F., Dihydropyrimidine calcium channel blockers. 4.Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents, J Med Chem., 35(17), 3254-3263 (1992)
  3. Grover G.J., Dzwonczyk S., McMullen D.M., Normadinan C.S., Sleph P.G. and Moreland S., Pharmacologic profile of the dihydropyrimidine calcium channel blockers SQ 32,547 and SQ 32,926 [correction of SQ 32,946], J Cardiovasc Pharmacol., 26(2), 289-294 (1995)
  4. Lanjewar K.R, Rahatgaonkar A.M, Chorghade M.S, and Saraf B.D., Synthesis and antimicrobial activity of 5-(2-aminothiazol-4-yl)-3,4-dihydro-4-phenyl pyrimidin-2(1H)-one, Ind. J.Chem., 48 B, 1732-1737 (2009)
  5. Sondhi, S. M., Jain, S., Dwivedi, A. D., Shukla, R. and Raghubir, R., Synthesis of condensed pyrimidines and their evaluation for anti-inflammatory and analgesic activities, Indian J.Chem., 47B, 136143 (2008)
  6. Sondhi, S. M., Dinodia, M., Rani, R., Shukla, R and Raghubir, R., Synthesis, anti-inflammatory and analgesic activity evaluation of some pyrimidines derivatives, Indian. J. Chem., 49B, 273281(2009)
  7. Sweet F., Fissekis J.D., Synthesis of 3,4-dihydro-2(1H)-pyrimidinones and the mechanism of Biginelli reaction, J Am Chem Soc., 95(26), 8741-8749 (1973)
  8. Folkers, K., Harwood, H.J. and Johnson, T.B., Researches on pyrimidines.CXXX.Sythesis of 2-keto-1,2,3,4-tetrahydropyrimidines, J. Am. Chem. Soc., 54(9), 3751-3758 (1932)
  9. Folkers, K., Hydrogenation and Hydrogenolysis of a 2-Keto-1,2,3,4-tetrahydropyrimidine derivative to 2-Benzyl and 2-Hexahydrobenzylbutanol-1, J. Am. Chem. Soc., 58(9), 1558-1560 (1936)
  10. Triggle, D.J., Ion channels as pharmacological receptors:The chirality of drug interactions, Chirality, 35-38 (1996)
  11. Bellemann, P., Innovative Approaches in Drug ResearchElsevier Science. Amsterdam, 23-46, (1986)
  12. Sehon, C.A., Wang, G.Z., Viet A.Q., Goodman, K.B., Dowdell, S.E., Elkins, P.A., Semus, S.F., Evans, C., Jolivette, L.J., Kirkpatrick, R.B., Dul, E., Khandekar, S.S., Yi T., Wright, L.L., Smith, G.K., Behm, D.J., Bentley, R., Doe, C.P., Hu E., Lee, D., Potent, selective and orally bioavailable dihydropyrimidine inhibitors of Rho kinase (ROCK1) as potential therapeutic agents for cardiovascular diseases, J Med Chem. 51(21), 6631-6634 (2008)
  13. Bossert, F. and Vater, W., 1,4-Dihydropyridines-a basis for developing new drugs, Med. Res. Rev., 291-324 (1989)
  14. Cleland, J.G.F., Daubert, J.C., Erdmann, E., The effect of cardiac resynchronization on morbidity and mortality in heart failure, N Engl J Med., 352 (15), 1539-1549 (2005)
  15. Bardy, G.H., Lee, K.L., Mark, D.B., Amiodarone or an implantable cardioverter defibrillator for Congestive heart failure, N Engl J Med, 352 (3), 225-237(2005)
  16. Bristow, M.R., Saxon, L.A., Boehmer, J., Cardiac resynchronization therapy with or without an implantable defibrillation in advanced chronic heart failure, N Engl J Med, 350, 2140-2150 (2004)
  17. Scherrer-Crosdie, M., Cocca-Spofford, D., Di Salvo T.G., Semigran, M.J., Dec, G.W. and Picard, M.H., Effect of vasnarione on cardiac function in patients with severe Congestive heart failure, J Am CollCardiol, 29, 325A (1997)
  18. Hernandez A.F., Harrington R.A., Comparativeeffectivenessofangiotensin-converting-enzymeinhibitors:Is an ace always an ace, CMAJ,178(10), 1316-1319 (2008)
  19. Healey, J.S., Baranchuk, A., Crystal, E., Prevention of atrial fibrillation with angiotensin converting enzyme inhibitors and angiotensin receptor blockers, J Am Coll Cardiol, 45, 1832-1839 (2005)
  20. Bakris G.L., Frohlich E.D., The evolution of antihypertensive therapy: An overview of four decades of experience, J Am Coll Cardiol, 14(7), 1595-1608 (1989)
  21. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L. Jr, Jones D.W., Materson B.J., Oparil S., Wright J.T. Jr, Roccella E.J., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289(19), 2560-2572 (2003)
  22. Wang, T.J., Ausiello, J.C., Stafford, R.S., Trends in antihypertensive drug advertising, Circulation, 2055-2057 (1999)
  23. Stafford R.S., Monti V., Furberg C.D., Ma J., Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States, Hypertension, 48(2), 213-218 (2006)
  24. Davis, B.R., Piller, L.B., Cutler, J.A., Furberg, C., Dunn, K., Franklin, S., Role of diuretics in prevention of heart failure: the antihypertensive treatment to prevent heart attack trial, Circulation, 113 (18), 2201-2210 (2006)
  25. Ohno, A., Naruse, M., Kato, S., Hosaka, M., Karuse, K., Demura, H., Endothelin specific antibodies decrease blood pressure and increase glomerular filtration rate and renal pressure flow in spontaneously hypertensive rats, J Hypertens, 10, 781-785 (1992)
  26. Bernadt-Monorozies, P., Poillenx, E., Suc, J.M., Evaluation of the tolerance and effectiveness of diltiazem LP 300 mg in hypertensive patients with chronic renal insufficiency, Ann Cordiol Angeiol, 47, 589-594 (1998)
  27. Schulte K.L., Meyer-Sabellek W.A., Haertenberger A., Thiede H.M., Roecker L., Distler A., Gotzen R., Antihypertensive and metabolic effects of diltiazem and nifedipine, Hypertension, 8(10) 859-865 (1986)
  28. Tuomilehto, J., Rastenyte, D., Birken hager, W., Effects of Calcium channel blocake in older patients with diabetes and systolic hypertension, N Engl J Med, 340, 677-684 (1999)
  29. Ohlstein, E.H., Douglas, S.A., Endothelin-1 modulates vascular smooth muscle structure and vasomotion:implications in cardiovascular pathology, Drug DevRes., 29, 108-128 (1993)
  30. Douglas, S.A., Gellai, M., Ezekiel, M., Ohlstein, E.H., BQ-123, a selective endothelin sub type A-receptor antagonist lowers blood pressure in different modes of hypertension, J Hypertens, 12, 561-567(1994)
  31. Katzung, B.G., Trevor A.J., Masters S.B., Vasodilators & the treatment of angina pectoris In:Basic and clinical Pharmacology, The Mc Graw-Hill companies, Inc, USA, 11th edition, 12 (2009)
  32. Hugenholtz, P.G., Michels, H.R., Nifedipine in the treatment of unstable angina,coronary spasm and myocardial ischaemic, Am J Cardiol, 47, 163-173 (1981)
  33. Waters, D.D., Theroux, P., Szachnic, J., Provacative testing with ergonovine to assess the efficiency of treatment with nifedipine, diltiazem and verapamil in variant angina, Am J Cardiol, 48, 123-130 (1981)
  34. Wijffels, M.C., Kirchhof, C.J., Dorland, R., Allessie, M.A., Atrial fibrillation begets atrial fibrillation, Circulation, 92, 1954-1968 (1995)
  35. Nichol, G., Mc Alister, F., Pham, B., Laupacis, A., Shea, B., Green, M., Tang, A., Wells, G., Meta analysis of randomized controlled trials of the effectiveness of anti-arrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation, Heart, 87 (6), 535-543 (2002)
  36. Zanelti, L.A., Sotalol., A new class III anti-arrhythmic agent, Clinical Pharmacy, 12, 883-891(1993)
  37. Lenz, T.L., Hilleman, D.E., A new class III anti-arrhythmic agents, Pharmacotherapy, 20 (7), 776-786 (2000)
  38. Nattel, S., Comparative mechanisma of action of antiarrhythmic drugs, Am J of Cardiology, 72 (16), 82F-86F (1993)
  39. Lucchesi, B.R., Chi, L., Friedrichs, G.S., Black, S.C., Uprichard, A.C.G., Antiarrhythmic versus antifibrillatory actions: inference from experimental studies, Am J Cardiol., 72(16), 25F-44F (1993)
  40. Beyer, T., Brachmann, J., Kubler, W., Comparative effects of d-sotalol and I-sotalol on the atrio ventricular node of the rabbit heart, J Cardiovascular Pharmacology, 22 (2), 240-246 (1993)
  41. Jorge, R., Kizer, Stephen, E., Epidermiological review of the Calcium channel clocker drugs, Arch. Interm. Med, 161, 1145-1158 (2001)
  42. Abernethy, D.R., Schwartz, J.B., Calcium antagonist drugs, N Engl J Med, 341, 1447-1457 (1999)
  43. Schwartz, A., Molecular and cellular aspects of Calcium channel antagonism, Am J Cardiol, 70, 6F- 8F (1992)
  44. Braunwald, E., Mechanism of action of calcium channel blocking agents, N Engl J .Med, 307, 1618-1627 (1982)
  45. Ene, M.D., Williamson, P.J., Robetrs, C.J.C., The naturiuresis following oral administration of Calcium antagonists nifedipine and nitrendipine, Br. J. Clin. Pharmacol, 19, 423-427 (1985)
  46. Fleckenstein, A., History of calcium antagonists, Circ Res, 52, 13-16 (1983)
  47. Curitus, B.M. and Caterall, W.A., Solubilization of calcium antagonist receptor from rat brain, J BiolChem, 258(12),7280-7283 (1983)
  48. Hajjar, R.J., Schmidt, U., Helm, P. and Gwathmey, J.K., Ca+2 sensitizer impair cardiac relaxation in failing human myocardium, J Pharmacol Exp Ther, 280, 247-254 (1997)
  49. Takahashi D., Oyunzul L., Onoue S., Ito Y., Uchida S., Simsek R., Gunduz M.G., Safak C., Yamada S., Structure activity relationships of receptor binding of 1,4-dihydropyridine derivatives, Biol Pharm Bull, 31(3), 473-479 (2008)
  50. Pedemonte N., Boido D., Moran O., Giampieri M., Mazzei M., Ravazzolo R., Galietta L.J.V., Structure Activity Relationship of 1,4-dihydropyridines as potentiators of cystic fibrosis transmembrane conductance regulator chloride channel, Mol Pharmacol, 72, 197-207 (2007)
  51. Kappe C.O., 4-Aryldihydropyrimidines via the Biginelli Condensation: Aza-Analogs of Nifedipine-Type Calcium Channel Modulators, Molecules, 1-9 (1998)
  52. Rovnyak G.C., Kimball S.D., Beyer B., Cucinotta G., DiMarco J.D., Gougoutas J., Hedberg A., Malley M., McCarthy J.P., Zhang R., Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators, J Med Chem, 38(1), 119-129 (1995)
  53. Sanguinetti, M.C., Kraft, D.S., Kass, R.S., Bay K8644 voltage dependent modulation of calcium channel current in heart cells, J. Gen Physiol, 88, 369-392 (1986)
  54. Schramm, M., Thomas, G., Towart, R., Novel dihydropyridines with positive ionotropic action through activation of calcium channels, Nature, 308, 535-537 (1983)
  55. Kloner, R.A., Nifedipine in ischemic heart disease, Circulation,92, 1074-1078 (1995)
  56. Godfraind, T., Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries, J Pharmacol Exp ther, 224, 443-450 (1983)
  57. Higashiyama, A., Watkins, M., Chen, Z. and Le Winter, M.M., Effect of EMD 57033 on contraction and relaxation in isolated rabbit heart, Circulation, 3094-3104 (1992)
  58. Ghosh M.N., Fundamentals of experimental pharmacology, nd edition, Scientific book agency, Calcutta, India, 3-5, 22-23, 92-93, (1984)
  59. Burn, J.H., Practical Pharmacology, Blackwell Scientific Publication Ltd. Oxford, 7-12, 25 and 30 (1952)
  60. Perry, W.L.M., Pharmacological experiments on isolated preparation, nd edition, E. & S., Livingstone, Edinburgh, 116 (1970)